Evidence map›Paper›PMID 34353626›Full record

ArticleMedicina clinica2022

Association of blood group A with hospital comorbidity in patients infected by SARS-CoV-2.

Álvaro Tamayo-Velasco, María Teresa Jiménez García, Alba Sánchez Rodríguez, Milagros Hijas Villaizan, Juana Carretero Gómez, José Pablo Miramontes-González

Abstract readCase Reports
In one paragraph

Article in Medicina clinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Álvaro Tamayo-VelascoHematología Clínica, Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario de Valladolid, Valladolid, España. Electronic address: alvarotv1993@gmail.com.
María Teresa Jiménez GarcíaHematología Clínica, Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Alba Sánchez RodríguezHematología Clínica, Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Milagros Hijas VillaizanHematología Clínica, Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Juana Carretero GómezMedicina Interna, Hospital de Zafra, Zafra, Badajoz, España.
José Pablo Miramontes-GonzálezServicio de Medicina Interna. Hospital Universitario Rio Hortega de Valladolid, Valladolid, España; Facultad de Medicina, Universidad de Valladolid, Valladolid, España. Electronic address: jpmiramontes@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesIn the pandemic caused by SARS-CoV-2, identifying which risk factors are associated with the most serious forms of the disease is important. Blood group A has been presented in various studies as a poor prognostic factor. The objective of this study was to evaluate whether patients with blood group A were associated with more important comorbidities, measured by the Charlson Index, which may explain their worse clinical evolution. PATIENTS AND

methodsA prospective and consecutive study examined 100 patients diagnosed with COVID-19 and admitted in March 2020. A multivariate linear regression model was used to evaluate the association of blood group A with the Charlson Index.

resultsPatients in group A had a higher Charlson Index (P=.037), rate of lymphopenia (P=.039) and thrombopenia (P=.014), and hospital mortality (P=.044). Blood group A was an independent factor associated with the Charlson Index (B 0.582, 95% CI 0.02-1.14, P=0.041).

conclusionsGroup A was independently associated with greater comorbidity, associated with an increase of 0.582 points in the Charlson Index compared to other blood groups. It was also associated with lower hospital mortality.

Indexed as

Blood Group AntigensCOVID-19ComorbidityHospital MortalityHospitalsHumansProspective StudiesSARS-CoV-2Blood Group AntigensBlood groupsCharlson IndexCOVID-19Grupos sanguíneosÍndice de CharlsonMortalidadMortality

Identifiers

PMID34353626
PMCPMC8279955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.